Penile lichen sclerosus et atrophicus treated with clobetasol dipropionate 0.05% cream: A retrospective clinical and histopathologic study - 07/09/11
Abstract |
Background: Treatment with clobetasol propionate 0.05% cream is effective against lichen sclerosus et atrophicus (LSA) of the vulva. Objective: The purpose of this study was to retrospectively evaluate whether clinical and histologic responses to topical clobetasol can be accomplished in penile LSA. Methods: A self-assessment questionnaire was obtained from 22 men with LSA, and a clinical examination was performed in 21 of them. Biopsy specimens from 15 cases were compared before and after treatment. Results: Itching, burning, pain, dyspareunia, phimosis, and dysuria decreased significantly (P < .001 to .05) after 1 to 2 daily applications, for a mean of 7.1 weeks (2-16 weeks). Additional operation for phimosis was required in 6 of the 22 men. All histologic LSA criteria were significantly (P < .01 to .05) reduced after treatment. Conclusion: Topical treatment of penile LSA with clobetasol propionate represents a safe and effective therapy with no risk of epidermal atrophy but with some potential for triggering latent infections, most importantly human papillomavirus. (J Am Acad Dermatol 1999;40:451-7.)
Le texte complet de cet article est disponible en PDF.Plan
 | Supported by a grant from the Swedish Welander-Finsen Foundation. |
| Reprint requests: Geo von Krogh, Department of Dermatovenereology, Karolinska Hospital, Box 120, 171 76 Stockholm, Sweden. |
 | 0190-9622/99/$8.00 + 0 16/1/95953 |
Vol 40 - N° 3
P. 451-457 - mars 1999 Retour au numéro
Article précédent
- Chronic idiopathic urticaria: Comparison of the clinical features of patients with and without anti-FcϵRI or anti-IgE autoantibodies
- R.A. Sabroe, P.T. Seed, D.M. Francis, R.M. Barr, A.Kobza Black, M.W. Greaves
- Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis
- Conleth A. Egan, Wendy J. Grant, Stephen E. Morris, Jeffrey R. Saffle, John J. Zone
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?